Drug intelligence / Profile preview

human umbilical cord-derived mesenchymal stem cells (CytoMed Therapeutics)

Development stage: Unknown
Lead developer: Beike Biotechnology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are an allogeneic cell therapy consisting of mesenchymal stem cells harvested from the Wharton's jelly of human umbilical cords. Developed jointly by CytoMed and Beike Biotech, these cells are characterized by low immunogenicity, high proliferative capacity, and potent immunomodulatory and anti-inflammatory properties. The therapeutic mechanism involves the suppression of T helper cell (TH1) responses, regulation of T and B cell activity, and targeted migration to inflamed tissues, such as the kidneys, via the CXCL10-CXCR3 signaling axis. hUC-MSCs are currently being investigated in Phase 2 clinical trials for the treatment of Class III or IV lupus nephritis as an adjunct to standard immunosuppressive therapy.

Other names: hUC-MSCWharton's jelly-derived mesenchymal stem cells

Beyond the preview

Go deeper on human umbilical cord-derived mesenchymal stem cells (CytoMed Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human umbilical cord-derived mesenchymal stem cells (CytoMed Therapeutics).

Explore the full profile